Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors

American Journal of Hematology - United States
doi 10.1002/ajh.24608
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Parathyroid Hormone Receptor Mediates the Anti-Myeloma Effect of Proteasome Inhibitors

Bone
EndocrinologyPhysiologyHistologyMetabolismDiabetes
2014English

Phase 1 Study of Ixazomib, an Investigational Proteasome Inhibitor, in Advanced Non-Hematologic Malignancies

Investigational New Drugs
OncologyPharmacology
2015English

Synthesis and Activity of Proteasome Inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry
MedicineDrug DiscoveryPharmacology
2013English

Preclinical Evaluation of Antitumor Activity of the Proteasome Inhibitor MLN2238 (Ixazomib) in Hepatocellular Carcinoma Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2018English

Inhibition of Proteasome Deubiquitinase Activity: A Strategy to Overcome Resistance to Conventional Proteasome Inhibitors?

Drug Resistance Updates
Cancer ResearchOncologyInfectious DiseasesPharmacology
2015English

Proteasome Inhibitors in Cancer Therapy

2004English

Advances in and Applications of Proteasome Inhibitors

Current Opinion in Chemical Biology
BiochemistryAnalytical Chemistry
2008English

Proteasome Inhibitors Block Development ofPlasmodium Spp.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1998English

Cardiotoxicity of Immune Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy